MCL1 and acute lymphoblastic leukemia: In proof of principle studies, we demonstrated that MCL1 silencing in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) PDX models correlates to response to pharmacological MCL1 inhibition.